Impact Factor
4.11
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.95
1,702 total citations
h5-index
47
h5 depth signal
Cited share
81.1%
241 of 297
Total citations
1,702
Citation footprint
Metric signal
5.80
External metric anchor
Self-citation
9.0%
154 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
679
Italy
230
China
151
Canada
140
Germany
112
Citing Fields of Research
Prostate Cancer
1,110
Urology
183
Oncology
46
Genetics & Genomics
41
Immunology
31
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,571
Articles tracked across the journal lifetime
Indexed publication set
297
241 cited publications
Last 12 months
128
10.7 publications/month
Open access share
38.3%
49 OA publications in the last year
Leading citing country
United States
679 citing publications
Leading citing field
Prostate Cancer
1,110 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v5n1, 2002-
v5n1, 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Prostate Cancer
Broad Categories
Neoplasms
Urology
Prostate Cancer
MeSH Descriptors
Prostatic Diseases
Prostatic Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1038/s41391-026-01168-7
Open DOI
MRI and PSMA PET/CT: Foes or friends for the early detection of prostate cancer?
02
DOI 10.1038/s41391-026-01153-0
Open DOI
Early apical release versus conventional (non-early apical release) holmium laser enucleation of the prostate: a systematic review and meta-analysis of postoperative urinary incontinence and functional outcomes
Background: Despite proven safety, efficacy, and durability of Holmium laser enucleation of the prostate (HoLEP), postoperative transient stress urine incontinence (SUI) was a concern for years. A technical modification of the original H...
03
DOI 10.1038/s41391-026-01166-9
Open DOI
Qualitative study on barriers and facilitators to genetic testing in Hispanic patients with prostate cancer
04
DOI 10.1038/s41391-026-01163-y
Open DOI
Cardiometabolic health’s influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer
Altered lipid metabolism, adiposity, and androgens have been linked to cardiac disease and prostate cancer. Adiposity increases risk of recurrence for prostate cancer and may enhance response to androgen receptor pathway inhibition (ARPI...
05
06
DOI 10.1038/s41391-026-01151-2
Open DOI
Fracture risk and fracture risk factor assessment among men at prostate cancer diagnosis
07
DOI 10.1038/s41391-026-01164-x
Open DOI
Artificial intelligence in prostate cancer care from performance to clinical integration
08
DOI 10.1038/s41391-026-01162-z
Open DOI
How does PSA change after water vapor therapy? A systematic review and meta-analysis
Introduction Prostate-specific antigen (PSA) kinetics following minimally invasive surgical therapies (MIST) for benign prostatic hyperplasia (BPH) remain incompletely characterized. Water vapor thermal therapy (Rezūm™) induces targeted ...
09
DOI 10.1038/s41391-026-01156-x
Open DOI
Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer
10
DOI 10.1038/s41391-026-01159-8
Open DOI
Variation in quality of physician communication in prostate cancer consultations
Background: Clear communication of treatment risks and benefits is essential for shared decision making (SDM) in prostate cancer (PC). However, the quality of physician communication in real-world consultations remains poorly characteriz...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
v. 1, no. 1 (Sept. 1997)20030121 Notice not published Printed on acid-free paper